- Conditions
- Lung Transplant
- Interventions
- Regadenoson infusion
- Drug
- Lead sponsor
- Christine Lau, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Premenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Adenosine, Magnetic Resonance Imaging, Regadenoson, Stress Management Therapy
- Biological · Procedure · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 55 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- MRI, Transthoracic Echocardiography, tonometry, EKG
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease, Diabetes Mellitus Type 2
- Interventions
- Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Disease
- Interventions
- regadenoson
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity, Endothelial Dysfunction, Decreased Vascular Flow
- Interventions
- Adenosine, Regadenoson
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- CAD
- Interventions
- MRI scan - obj 1, MRI scans - obj 2, MRI scans - obj 3, MRI scans - obj 4
- Device
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ischemia
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Veterans Referred to the St. Louis VAMC Stress Tes
- Interventions
- Regadenoson myocardial perfusion imaging stress test, Arm exercise electrocardiographic stress test, Treadmill electrocardiographic stress test, Coronary artery calcium score and cardiac computed tomographic angiography
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Coronary Artery Disease
- Interventions
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
- Radiation
- Lead sponsor
- Cell>Point LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- regadenoson, overencapsulated caffeine, technetium, placebo
- Drug · Radiation
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
- Conditions
- Coronary Artery Disease
- Interventions
- Image Quality, Diagnostic Accuracy
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
- Interventions
- regadenoson
- Drug
- Lead sponsor
- Marvin W. Kronenberg, M.D.
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- MRI Scans
- Interventions
- Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cardiac Function
- Interventions
- regadenoson
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Westminster, Maryland
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Drug · Procedure
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 60
- States / cities
- Mobile, Alabama • Fremont, California • Long Beach, California + 52 more
- Conditions
- Coronary Artery Disease
- Interventions
- Antigravity treadmill (Alter-G), Conventional treadmill/regadenoson
- Device
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson, Adenosine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Pulmonary Hypertension
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Timothy M. Bateman
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Coronary Artery Disease
- Interventions
- PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
- Diagnostic Test · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia